Alaunos Therapeutics | ZIOP - Operating Expenses


Alaunos Therapeutics reported $1.01M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bioline Rx USD 3.48M 99K Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celltrion KRW 119.22B 21.46B Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Cspc Pharmaceutical CNY 5.91B 512.77M Dec/2025
Curis USD 11.52M 2.5M Mar/2026
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Divis Laboratories Ltd INR 19.51B 660M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 17.83B 388M Jun/2026
Kangmei Pharma CNY 1.22B 130.32M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Merck USD 15.77B 2.4B Jun/2026
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Novartis USD 10.2B 912M Jun/2026
Organigram Holdings CAD 69.59M 14.08M Mar/2026
Ovoca Bio EUR 173K 990K Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Pharma Mar EUR 51.01M 8.73M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Qiagen NV USD 393.64M 17.95M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sartorius EUR 747.8M 9.4M Jun/2026
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
TG Therapeutics USD 218.66M 48.54M Jun/2026
Tilray USD 237.52M 17.34M Sep/2025
Verastem USD 63.57M 4.56M Mar/2026
Zealand Pharma A/S 573M 202.97M Mar/2026
Zz Pientze Pharmaceu CNY 1.45B 431.06M Jun/2026